Sugi Predict

Sugi Predict / Compounds / SCHEMBL1644002

SCHEMBL1644002

SCHEMBL1644002

CC(=O)Nc1ccccc1S(C)(=O)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.55
▸ HPGD P15428 1/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ SLC40A1 Q9NP59 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ PKM P14618 1/20 0.50
▸ JAK1 P23458 1/20 0.49
▸ TYK2 P29597 1/20 0.49
▸ TSHR P16473 3/20 0.49
▸ LMNA P02545 1/20 0.49
▸ POLB P06746 2/20 0.49
▸ MAOA P21397 1/20 0.49
▸ BCAT2 O15382 1/20 0.49
▸ CA1 P00915 1/20 0.49
▸ CA2 P00918 1/20 0.49
▸ CA9 Q16790 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ MAPK1 P28482 1/20 0.47
▸ NAPRT Q6XQN6 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7108586 0.86 NPC1 (0.53) ALDH1A1SMN1; SMN2JAK1TYK2BCAT2
SCHEMBL498547 0.85 ALDH1A1 (0.55) ALDH1A1HPGDSMN1; SMN2SLC40A1HTT
SCHEMBL30673688 0.85 ALDH1A1 (0.55) ALDH1A1HPGDSMN1; SMN2SLC40A1HTT
SCHEMBL2575446 0.85 CA1 (0.49) ALDH1A1SMN1; SMN2JAK1TYK2POLB
SCHEMBL2342479 0.85 ALDH1A1 (0.55) ALDH1A1HPGDSMN1; SMN2SLC40A1HTT
SCHEMBL30752023 0.85 CA1 (0.49) ALDH1A1SMN1; SMN2JAK1TYK2POLB
SCHEMBL28816355 0.85 BCAT2 (0.53) ALDH1A1HPGDPOLBBCAT2CA1
SCHEMBL29350373 0.83 ALDH1A1 (0.53) ALDH1A1HPGDSMN1; SMN2SLC40A1HTT
SCHEMBL1279094 0.83 ALDH1A1 (0.53) ALDH1A1HPGDSMN1; SMN2SLC40A1HTT
SCHEMBL31309573 0.83 CA1 (0.70) ALDH1A1HPGDCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024196936-A2 LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME SILA NANOTECHNOLOGIES, INC. (US) 2024-09-26 — — WO claimed
US-20240322244-A1 LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME SILA NANOTECHNOLOGIES, INC. 2024-09-26 — — US claimed
JP-4665239-B2 — — 2011-04-06 — — JP claimed
JP-2002512230-A — — 2002-04-23 — — JP claimed
EP-1071668-A1 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS Du Pont Pharmaceuticals Company (US) 2001-01-31 — — EP claimed
WO-1999054308-A1 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS DU PONT PHARMACEUTICALS COMPANY (US) 1999-10-28 — — WO claimed
WO-2024196936-A2 LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME SILA NANOTECHNOLOGIES, INC. (US) 2024-09-26 — — WO disclosed
US-20240322244-A1 LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME SILA NANOTECHNOLOGIES, INC. 2024-09-26 — — US disclosed
WO-2024074611-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2024-04-11 — — WO disclosed
US-10093667-B1 Coumarinyl-thiazole-sulfonyl conjugate and preparation thereof COMSATS INSTITUTE OF INFORMATION TECHNOLOGY (PK) 2018-10-09 — — US disclosed
WO-2017177979-A1 HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE 中国科学院上海有机化学研究所 2017-10-19 — — WO disclosed
WO-2006083673-A2 PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES ABBOTT LABORATORIES (US) 2006-08-10 — — WO disclosed
EP-1417177-A4 ACYLSEMICARBAZIDES AS CYCLIN DEPENDENT KINASE INHIBITORS USEFUL AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS BRISTOL MYERS SQUIBB PHARMA CO (US) 2005-10-19 — — EP disclosed
WO-2003007883-A2 ACYLSEMICARBAZIDES AS CYCLIN DEPENDENT KINASE INHIBITORS USEFUL AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2003-01-30 — — WO disclosed
CN-1297442-A 5-aminoindeno [1,2-c] pyrazol-4-ones as anti-cancer and anti-proliferative agents DU PONT PHARM CO (US) 2001-05-30 — — CN disclosed
EP-1071668-A1 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS Du Pont Pharmaceuticals Company (US) 2001-01-31 — — EP disclosed
WO-1999054308-A1 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS DU PONT PHARMACEUTICALS COMPANY (US) 1999-10-28 — — WO disclosed
US-4600797-A NITRATING AN AMINOBENZENE WHICH HAS A PROTECTEDD AMINO GROUP BAYER AKTIENGESELLSCHAFT (DE) 1986-07-15 — — US disclosed
EP-0049711-B1 PROCESS FOR THE PRODUCTION OF NITRO-AMINO-BENZENES BAYER AG (DE) 1984-02-29 — — EP disclosed
EP-0049711-A1 Process for the production of nitro-amino-benzenes BAYER AG (DE) 1982-04-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10093667-B1 Coumarinyl-thiazole-sulfonyl conjugate and preparation thereof OPRK1, OPRL1, OGFR ALDH1A1 63/4885HPGD 1533/4885SMN1; SMN2 1455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.